Analyst Price Targets — ABEO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2026 7:53 pm | Stephen Willey | Stifel Nicolaus | $17.00 | $4.76 | StreetInsider | Abeona Therapeutics (ABEO) PT Lowered to $17 at Stifel on Zevaskyn sales estimates |
| May 16, 2025 12:02 pm | Stephen Willey | Stifel Nicolaus | $20.00 | $6.10 | TheFly | Abeona Therapeutics price target lowered to $20 from $21 at Stifel |
| March 5, 2025 12:18 pm | — | Oppenheimer | $16.00 | $5.26 | TheFly | Abeona Therapeutics initiated with an Outperform at Oppenheimer |
| November 14, 2022 1:42 pm | — | Leerink Partners | $6.00 | $4.15 | Benzinga | SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6 |
Latest News for ABEO
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a >$4B cumulative revenue opportunity. Profitability is achievable by treating just three RDEB patients per month; demand doubled from 50 to 100 eligible patients,…
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about…
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABEO.
U.S. House Trading
No House trades found for ABEO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.